17 countries have signed on to purchase the Coronavirus vaccine produced by Oxford-AstraZeneca and have ordered a total of 2.5 billion (250 million) doses. An analysis by Duke University revealed this. In this way, this vaccine will be the most purchased vaccine worldwide.
At the same time, the second number is that of Novavax of America, which has ordered 1.3 billion (130 million) doses. Then comes the number of vaccines prepared by Sanofi-GSK, which has received a dose order of 732 million (about 73 million).
This is followed by the Pfizer-BioNotech vaccine, which has recently been approved for use in the UK. Pfizer has been ordered with 646 million (about 64 million) doses. A total of 19 vaccine manufacturers have been ordered with a dosage of 7.1 billion (7.1 billion).
India signed an agreement with three vaccine companies
An analysis of Duke University's 'Launch and Scale Speedometer' showed that India has entered into deals with three global vaccine candidates. At the same time, the European Union and the United States have signed deals with six vaccine companies. The 'Launch and Scale Speedometer' is updated every two weeks.
Canada and the UK have signed deals with seven vaccine companies for 350 million (350 million) doses. On the other hand, India has 500 million (50 crores) of Oxford-AstraZeneca vaccine, one billion (one billion) of American company Novavax Inc. and 100 million (100 million) of Sputnik-V vaccine prepared by Russia's Gamalaya Research Institute Dose is ordered.
India will need 2.6 billion doses of vaccine
Apart from these, Bharat Biotech, a domestic vaccine candidate, entered the third phase of testing on Wednesday. Dr. V Ravi, a member of the Expert Committee on Corona Vaccine, said that all the vaccine candidates, all of them said that two doses of vaccine would be needed to prevent infection, so theoretically India should be able to cover its population. Would require 2.6 billion (2.6 billion) doses.
He said, but it is not practical to vaccinate all over the country. Also, it is not necessary that once we cover more than 60 percent of the population, we will see this disease is controlled. Therefore, I think the commitment to these doses should be sufficient.